Browsing by Author "Birtaş Ateşoğlu, Elif"
Now showing items 1-2 of 2
-
CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: A multicenter study
Demirci, Ufuk; Kırkızlar, Hakkı Onur; Ümit, Elif Gülsüm; Gürsoy, Vildan; Pınar, İbrahim Ethem; Özkalemkaş, Fahir; Güven, Zeynep Tuğba; Kaynar, Leylagül; Keklik Karadağ, Fatma; Saydam, Güray; Ekinci, Ömer; Merter, Mustafa; Aras, Merih Reis; Albayrak, Murat; Karaman Gülsaran, Sedanur; Baş, Volkan; Balık Aydın, Berrin; Beköz, Hüseyin Saffet; Can, Ferda; Dilek, İmdat; Mehtap, Özgür; Öztürk, Erman; Çobanoğlu Şimşek, Bengü; Yıldırım, Murat; Aylı, Meltem; Ataş, Ünal; Salim, Ozan; Ayer, Mesut; Birtaş Ateşoğlu, Elif; Akay, Olga Meltem; Kurt Yüksel, Meltem; Paydaş, Semra; Korkmaz, Selçuk; Öz Puyan, Fulya; Demir, Ahmet Muzaffer (Springer Science and Business Media Deutschland GmbH, 2022)Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and comprises a heterogeneous group of disease. While classification of B-cell lymphomas has been evolving to include clonality ... -
Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
Ferhanoğlu, Burhan; Gülbaş, Zafer; Uzay, Ant; Özcan, Muhit; Özkalemkaş, Fahir; Dal, Mehmet Sinan; Kalyon, Hakan; Akay, Olga Meltem; Deveci, Burak; Bekoz, Hüseyin; Sevindik, Ömür Gökmen; Toptaş, Tayfur; Yılmaz, Asu Fergün; Koyun, Derya; Alkış, Nihan; Birtaş Ateşoğlu, Elif (American Society of Hematology, 2022)Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response ...
